Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Bangladesh
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
- Interventions
- Other: No treatment given
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2092
- Registration Number
- NCT00839878
- Locations
- 🇧🇩
Novo Nordisk Investigational Site, Dhaka, Bangladesh
Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects
Phase 1
Completed
- Conditions
- Haemophilia ACongenital Bleeding Disorder
- Interventions
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 23
- Registration Number
- NCT00837356
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Zürich, Switzerland
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Singapore
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetes
- Interventions
- Other: No treatment given
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 854
- Registration Number
- NCT00836030
- Locations
- 🇸🇬
Novo Nordisk Investigational Site, Singapore, Singapore
Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 339
- Registration Number
- NCT00834262
- Locations
- 🇮🇱
Novo Nordisk Investigational Site, Kfar Saba, Israel
Effect of Renal Impairment on the Pharmacokinetics of NN9535
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2Renal ImpairmentDiabetes
- Interventions
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 62
- Registration Number
- NCT00833716
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Knoxville, Tennessee, United States
Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 75
- Registration Number
- NCT00832182
- Locations
- 🇸🇮
Novo Nordisk Investigational Site, Ljubljana, Slovenia
Observational Study to Evaluate the Safety of Levemir® in Type 2 Diabetes
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 18481
- Registration Number
- NCT00825643
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT00825253
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT00824668
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Congenital Bleeding DisorderHealthy
- Interventions
- Drug: placebo
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2015-01-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT00822185
© Copyright 2025. All Rights Reserved by MedPath